Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Virpax Pharmaceuticals, Inc. (VRPX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT TO EMPLOYMENT AGREEMENT"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "VIRPAX PHARMACEUTICALS REPORTS 2023 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS"
07/26/2023 8-K Quarterly results
06/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT TO BY-LAWS, DATED JUNE 5, 2023"
06/07/2023 ARS Form ARS - Annual Report to Security Holders:
06/07/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/14/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 SC 13G/A Mack Anthony P. reports a 26.1% stake in VIRPAX PHARMACEUTICALS, Inc.
01/26/2023 SC 13G/A Kepos Capital LP reports a 0% stake in Virpax Pharmaceuticals, Inc.
01/10/2023 SC 13G/A SABBY MANAGEMENT, LLC reports a 8.4% stake in Virpax Pharmaceuticals, Inc.
12/29/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/22/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
Docs: "PRESS RELEASE OF VIRPAX PHARMACEUTICALS, INC. ISSUED NOVEMBER 9, 2022"
10/19/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/07/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
07/25/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/21/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/15/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/15/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/16/2022 8-K Quarterly results
05/06/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/31/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "PRESS RELEASE OF VIRPAX PHARMACEUTICALS, INC. ISSUED MARCH 31, 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy